These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9209471)

  • 61. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
    Peruzzi B; Athauda G; Bottaro DP
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 63. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
    An J; Fisher M; Rettig MB
    Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma.
    Williamson SR; Zhang S; Eble JN; Grignon DJ; Martignoni G; Brunelli M; Wang M; Gobbo S; Baldridge LA; Cheng L
    Am J Surg Pathol; 2013 Aug; 37(8):1131-9. PubMed ID: 23648463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location.
    Maranchie JK; Afonso A; Albert PS; Kalyandrug S; Phillips JL; Zhou S; Peterson J; Ghadimi BM; Hurley K; Riss J; Vasselli JR; Ried T; Zbar B; Choyke P; Walther MM; Klausner RD; Linehan WM
    Hum Mutat; 2004 Jan; 23(1):40-6. PubMed ID: 14695531
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome.
    Decker HJ; Gemmill RM; Neumann HP; Walter TA; Sandberg AA
    Cancer Genet Cytogenet; 1989 Jun; 39(2):289-93. PubMed ID: 2568884
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Prevention of renal carcinoma: the nutri-genetic approach].
    Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
    J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Establishment of experimental conditions for the rapid detection of mutations in the von Hippel-Lindau gene by parallel temperature gradient gel electrophoresis.
    Hernández A; Meyer A; Enczmann J; Ackermann R; Wernet P
    Electrophoresis; 1999 Jul; 20(10):1958-61. PubMed ID: 10451103
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Involvement of multiple loci on chromosome 3 in renal cell cancer development.
    van den Berg A; Buys CH
    Genes Chromosomes Cancer; 1997 Jun; 19(2):59-76. PubMed ID: 9171996
    [TBL] [Abstract][Full Text] [Related]  

  • 72. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer].
    Mikhaĭlenko DS; Grigor'eva MV; Rusakov IG; Kurynin RV; Popov AM; Peters MV; Matveev VB; Iakovlev ES; Nosov DA; Liubchenko LN; Tiuliandin SA; Strel'nikov VV; Zaletaev DV
    Mol Biol (Mosk); 2012; 46(1):71-81. PubMed ID: 22642103
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Familial non-syndromic clear cell renal cell carcinoma.
    Woodward ER
    Curr Mol Med; 2004 Dec; 4(8):843-8. PubMed ID: 15579031
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?
    Batavia AA; Schraml P; Moch H
    Histopathology; 2019 Jan; 74(1):60-67. PubMed ID: 30565303
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
    Pause A; Lee S; Lonergan KM; Klausner RD
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
    [TBL] [Abstract][Full Text] [Related]  

  • 78. VHL protein alterations in sporadic renal cell carcinoma.
    Giménez-Bachs JM; Salinas-Sánchez AS; Sánchez-Sánchez F; Lorenzo-Romero JG; Donate-Moreno MJ; Pastor-Navarro H; Carrión-López P; Escribano-Martínez J; Virseda-Rodríguez JA
    Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):784-9. PubMed ID: 17919893
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors.
    Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P
    Carcinogenesis; 2002 May; 23(5):809-15. PubMed ID: 12016154
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
    Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
    Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.